Bio Star Of Bethlehem

Dosage for Ornithogalum Umbellatum Flowering Top is highly individualized and depends strictly on the purpose of administration and the patient's sensitivity level.

Diagnostic Testing

For skin prick testing, a single drop of the concentrated extract (typically 1:10 or 1:20 w/v) is applied to the skin. For intradermal testing, 0.02 mL to 0.05 mL of a highly diluted extract (e.g., 100 PNU/mL) is injected.

Allergen Immunotherapy (SIT)

• Build-up Phase: Treatment usually begins with a very low dose (e.g., 0.05 mL of a 1:10,000 dilution) administered subcutaneously once or twice a week. The dose is gradually increased over 3 to 6 months.
• Maintenance Phase: Once the target dose is reached (e.g., 0.5 mL of a 1:100 or 1:10 dilution), the interval between injections is increased to every 2 to 4 weeks.

Ornithogalum Umbellatum Flowering Top may be used in children, but extreme caution is required. Pediatric dosing is generally based on the same titration principles as adult dosing, but the starting concentration may be even lower to minimize the risk of systemic reactions. Clinical studies have shown that immunotherapy is generally safe for children aged 5 and older; use in children under 5 requires a specialized risk-benefit analysis by a pediatric allergist.

Renal Impairment

No specific dosage adjustments are typically required for renal impairment when used as a diagnostic allergen. However, if systemic adrenergic effects are a concern, patients with severe renal failure should be monitored more closely for prolonged activity of metabolites.

Hepatic Impairment

Patients with significant hepatic dysfunction may have reduced clearance of the alkaloid components. While standardized allergen doses are small, caution is advised in patients with Child-Pugh Class C impairment.

Elderly Patients

Geriatric patients are at a higher risk for adverse cardiovascular events from the adrenergic properties of this substance. Dosing should be approached conservatively, often starting at the lowest possible concentration, particularly in patients with pre-existing hypertension or coronary artery disease.

Standardized extracts of Ornithogalum Umbellatum Flowering Top are almost exclusively administered in a clinical setting.

• Injections: These must be given subcutaneously, usually in the posterior aspect of the upper arm. They should never be given intravenously.
• Observation: Patients must remain in the medical office for at least 30 minutes following an injection to monitor for signs of a systemic allergic reaction (anaphylaxis).
• Storage: Extracts must be kept refrigerated at 2°C to 8°C (36°F to 46°F). Do not freeze, as this can denature the allergenic proteins and render the treatment ineffective or dangerous.

In immunotherapy, consistency is vital. If a dose is missed during the build-up phase, the next dose may need to be reduced or the previous dose repeated to maintain safety. If the maintenance dose is delayed by more than 2 weeks, your doctor will likely reduce the dose for the next injection to prevent a reaction. Never attempt to 'double up' on doses to catch up.

An overdose of Ornithogalum Umbellatum Flowering Top can lead to severe systemic reactions.

• Signs: Rapid heart rate (tachycardia), high blood pressure (hypertension), tremors, severe anxiety, or a systemic allergic reaction (hives, swelling of the throat, difficulty breathing).
• Emergency Measures: Immediate administration of epinephrine is the primary treatment for an overdose-induced allergic reaction. Supportive care with oxygen, intravenous fluids, and antihistamines may be required in a hospital setting.

> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or frequency without medical guidance, as this significantly increases the risk of life-threatening reactions.

Most patients receiving Ornithogalum Umbellatum Flowering Top extracts for testing or therapy will experience localized reactions at the site of administration. These are generally expected and include:

• Local Erythema: Redness at the injection site that may feel warm to the touch.
• Pruritus: Intense itching at the site of injection or skin test.
• Local Edema: Swelling or the formation of a 'wheal' (a raised, itchy bump) that usually subsides within 24 hours.
• Mild Fatigue: Some patients report feeling tired or 'run down' for a few hours following immunotherapy.

As the dose increases during the build-up phase of immunotherapy, systemic but non-life-threatening symptoms may occur:

• Generalized Urticaria: Hives appearing on parts of the body away from the injection site.
• Rhinitis: Sneezing, runny nose, or nasal congestion.
• Headache: A dull, throbbing sensation, potentially linked to the adrenergic effects on blood vessels.
• Gastrointestinal Upset: Mild nausea or abdominal cramping.

• Angioedema: Deep tissue swelling, often affecting the lips, eyelids, or extremities.
• Tachycardia: An abnormally rapid heart rate, potentially exceeding 100 beats per minute at rest.
• Hypotension: A sudden drop in blood pressure, which can lead to dizziness or fainting.

> Warning: Stop using Ornithogalum Umbellatum Flowering Top and call your doctor immediately or seek emergency care if you experience any of the following symptoms of anaphylaxis:

• Difficulty Breathing: Wheezing, chest tightness, or a sensation that the throat is closing.
• Swelling of the Tongue or Throat: This can lead to airway obstruction and is a medical emergency.
• Rapid Pulse or Palpitations: A feeling that the heart is racing or skipping beats, which may be accompanied by chest pain.
• Confusion or Loss of Consciousness: Often a sign of severe circulatory collapse.
• Cyanosis: A bluish tint to the lips or fingernails, indicating a lack of oxygen.

Prolonged use of allergenic extracts for immunotherapy is generally well-tolerated over several years. However, some patients may develop 'late-phase reactions,' which involve swelling and soreness that appear 6 to 12 hours after an injection. There is no evidence that long-term use of these extracts causes organ damage, provided that systemic reactions are avoided. The adrenergic components, if used chronically in high doses, could theoretically contribute to cardiac hypertrophy or chronic hypertension, though this is not typical in standard allergenic dosing.

While Ornithogalum Umbellatum Flowering Top itself may not have a specific individual black box warning, it falls under the general FDA class warning for Allergenic Extracts:

WARNING: RISK OF SEVERE ALLERGIC REACTIONS

• Allergenic extracts can cause severe life-threatening systemic reactions, including anaphylaxis.
• This product should only be administered by physicians who are exceptionally experienced in the treatment of allergic diseases and the management of systemic reactions.
• Patients must be observed for at least 30 minutes after administration.
• Patients with unstable asthma or those taking beta-blockers are at an increased risk for severe outcomes if a reaction occurs.

Report any unusual symptoms or persistent reactions to your healthcare provider immediately.

Ornithogalum Umbellatum Flowering Top is a potent biological agent. It must be used with extreme caution in patients with a history of severe asthma, as they are more likely to suffer fatal bronchospasm during a systemic reaction. Patients must be educated on the signs of anaphylaxis and may be required to carry an epinephrine auto-injector (e.g., EpiPen) while undergoing treatment.

No specific FDA black box warning exists for Ornithogalum Umbellatum Flowering Top as a standalone chemical; however, as noted in the side effects section, it is subject to the mandatory class-wide black box warning for all Standardized and Non-Standardized Allergenic Extracts. This warning emphasizes the risk of sudden, life-threatening anaphylaxis and the necessity of administration in a facility equipped with emergency resuscitative equipment.

• Allergic Reactions / Anaphylaxis Risk: This is the primary concern. Reactions can occur even in patients who have previously tolerated the extract. The risk is higher during the 'build-up' phase of therapy or when switching to a new vial of extract.
• Cardiovascular Risk: Due to its classification as an alpha and beta-adrenergic agonist, this substance can increase myocardial oxygen demand. It should be used with caution in patients with unstable angina, recent myocardial infarction (heart attack), or severe cardiac arrhythmias.
• Asthma Status: Immunotherapy should be withheld if a patient is experiencing an acute asthma exacerbation or if their peak flow is significantly below their personal best.
• Infection: Injections should be deferred if the patient has a fever or a significant respiratory infection, as this may lower the threshold for a systemic reaction.

Patients undergoing long-term therapy with Ornithogalum Umbellatum Flowering Top should have the following monitored:

• Pulmonary Function Tests (PFTs): To ensure asthma is well-controlled.
• Injection Site Observation: To track the size of local reactions, which can predict future systemic risks.
• Vital Signs: Blood pressure and heart rate should be checked if the patient feels unwell following administration.

In general, this substance does not cause sedation. However, if a patient experiences a systemic reaction or receives epinephrine to treat a reaction, they may experience tremors, nervousness, or dizziness, which would impair their ability to drive or operate heavy machinery safely.

Alcohol consumption should be avoided on the day of an allergy injection. Alcohol can cause vasodilation (widening of blood vessels), which may accelerate the absorption of the allergen and increase the risk or severity of a systemic reaction.

Immunotherapy is typically a 3-to-5-year commitment. Stopping suddenly will not cause a withdrawal syndrome, but the patient's allergic symptoms will likely return to their baseline levels. If the treatment is stopped for several weeks and then restarted, the doctor must significantly reduce the dose to ensure safety.

> Important: Discuss all your medical conditions, especially heart or lung problems, with your healthcare provider before starting Ornithogalum Umbellatum Flowering Top.

• Non-Selective Beta-Blockers (e.g., Propranolol, Nadolol): These drugs are strictly contraindicated in patients receiving allergenic extracts. If a patient on a beta-blocker has an anaphylactic reaction, the beta-blocker will prevent epinephrine from working effectively, making the reaction potentially fatal.
• MAO Inhibitors (e.g., Phenelzine, Selegiline): Because Ornithogalum Umbellatum has adrenergic agonist properties, combining it with MAOIs can lead to a hypertensive crisis (dangerously high blood pressure) due to the inhibition of catecholamine metabolism.

• Tricyclic Antidepressants (TCAs): Drugs like Amitriptyline can potentiate the effects of adrenergic agonists, increasing the risk of tachycardia and hypertension.
• Other Sympathomimetics: Use with Pseudoephedrine or other stimulants can have an additive effect on heart rate and blood pressure.
• Digoxin: Since the plant Ornithogalum umbellatum naturally contains cardiac glycosides, there is a theoretical risk of additive toxicity with Digoxin, leading to arrhythmias.

• Antihistamines: While often used to treat allergies, taking a high dose of antihistamines right before an allergy test can cause a 'false negative' result by suppressing the wheal and flare reaction.
• Systemic Corticosteroids: Long-term use of steroids may mask the early signs of an allergic reaction or alter the immune response to immunotherapy.

• Caffeine: High intake of caffeine can worsen the tremors or tachycardia associated with the adrenergic properties of the extract.
• Cross-Reactive Foods: Patients allergic to Ornithogalum may experience 'Oral Allergy Syndrome' when eating related plants in the Liliaceae family (e.g., onions, garlic, asparagus), though this interaction is immunological rather than chemical.

• St. John's Wort: May alter the metabolism of alkaloid components through CYP3A4 induction.
• Ephedra/Ma Huang: Could dangerously increase the sympathomimetic (stimulant) effects of the extract.

• Skin Tests: As mentioned, antihistamines and certain antidepressants (like mirtazapine) can interfere with diagnostic skin testing for up to 7 days after the last dose.
• Catecholamine Tests: Systemic absorption of the extract may temporarily elevate urinary or plasma catecholamine levels, potentially interfering with tests for pheochromocytoma.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, especially those for blood pressure, depression, or heart rhythm.

Ornithogalum Umbellatum Flowering Top must NEVER be used in the following circumstances:

• Previous Severe Systemic Reaction: If a patient has had a life-threatening reaction to this specific extract in the past.
• Unstable Asthma: Patients whose asthma is not well-controlled (e.g., FEV1 consistently below 70% of predicted) are at an unacceptably high risk of death from bronchospasm.
• Current Beta-Blocker Therapy: Due to the inability to treat anaphylaxis effectively with epinephrine.
• Severe Immunodeficiency: Patients with compromised immune systems may not respond appropriately to immunotherapy and are at higher risk for complications.

These conditions require a careful risk-benefit analysis by a specialist:

• Pregnancy: While maintenance immunotherapy can often be continued, starting a new course of Ornithogalum Umbellatum Flowering Top during pregnancy is generally avoided due to the risk of maternal anaphylaxis, which can cause fetal hypoxia (lack of oxygen to the baby).
• Severe Coronary Artery Disease: The adrenergic stress of a potential reaction may trigger a cardiac event.
• Autoimmune Disorders: There is a theoretical risk that immunotherapy could exacerbate certain autoimmune conditions.

Patients who are known to be allergic to other members of the Liliaceae family (such as Tulips, Hyacinths, or Lilies) may exhibit cross-sensitivity to Ornithogalum Umbellatum Flowering Top. This means they are more likely to have a reaction to the extract even if they have never been exposed to it before.

> Important: Your healthcare provider will evaluate your complete medical history, including all allergies and current medications, before prescribing or administering Ornithogalum Umbellatum Flowering Top.

Ornithogalum Umbellatum Flowering Top is generally categorized similarly to FDA Category C. There are no adequate and well-controlled studies in pregnant women. The primary risk is not direct teratogenicity (birth defects) from the extract itself, but rather the risk of systemic anaphylaxis in the mother. Anaphylaxis can lead to uterine contractions and placental hypoperfusion (reduced blood flow), which can result in fetal distress or death. Therefore, initiating immunotherapy during pregnancy is not recommended. If a patient is already on a stable maintenance dose and becomes pregnant, the physician may choose to continue the treatment at the same or a slightly reduced dose.

It is not known whether the components of Ornithogalum Umbellatum Flowering Top are excreted in human milk. Because most of the active ingredients are large proteins or are administered in very small quantities, the risk to a nursing infant is considered low. However, breastfeeding mothers should be monitored for any signs of allergic reactions in the infant, such as hives or unexplained irritability.

Allergen immunotherapy using Ornithogalum Umbellatum Flowering Top is generally considered safe for children 5 years of age and older. The efficacy in younger children has not been as extensively studied. Pediatric patients must be able to communicate symptoms of an impending reaction (e.g., 'my throat feels itchy' or 'my chest hurts'). Growth parameters are not affected by the use of these extracts.

Patients over the age of 65 are at a higher risk for adverse reactions due to the likelihood of comorbid conditions such as hypertension, heart disease, or chronic obstructive pulmonary disease (COPD). Geriatric patients are also more likely to be taking medications that interact with adrenergic agonists. In this population, the diagnostic wheal-and-flare response may be diminished due to age-related changes in skin reactivity, leading to potential under-diagnosis.

No formal studies have been conducted in patients with renal impairment. While the proteins are not cleared renally, any systemically absorbed alkaloids or catecholamine-like substances may have a prolonged half-life. Monitoring for signs of adrenergic overstimulation is recommended in patients with a GFR below 30 mL/min.

Caution is advised in patients with severe hepatic impairment (Child-Pugh Class C). The liver is responsible for the metabolism of many small molecules found in botanical extracts. Reduced hepatic clearance could theoretically increase the systemic duration of the extract's adrenergic effects.

> Important: Special populations require individualized medical assessment and closer monitoring by a healthcare professional.

Ornithogalum Umbellatum Flowering Top acts through two primary pathways. First, as an Allergenic Extract, it interacts with the immune system's B-cells and T-cells. Upon administration, the antigenic proteins are taken up by antigen-presenting cells (APCs), which then present them to T-lymphocytes. In allergic individuals, this initially reinforces Th2 cell activity. However, repeated, controlled exposure during immunotherapy induces the production of regulatory T-cells (Tregs) and the secretion of IL-10 and TGF-beta, which suppress the allergic response.

Second, the extract contains alkaloids and potentially cardiac glycosides (such as convallatoxin and rhodexin A) that act as Adrenergic Agonists. These molecules bind to G-protein coupled receptors (GPCRs). Alpha-1 binding activates the Gq pathway, increasing intracellular calcium and causing smooth muscle contraction. Beta-binding activates the Gs pathway, increasing cyclic AMP (cAMP), which leads to increased heart rate (Beta-1) and smooth muscle relaxation in the bronchioles (Beta-2).

• Onset of Action: For diagnostic skin testing, the onset is rapid, with a wheal appearing within 15-20 minutes. For immunotherapy, the 'desensitization' effect takes months to develop.
• Duration of Effect: Local skin reactions typically resolve within 2 to 24 hours. Systemic adrenergic effects, if they occur, usually last 1 to 4 hours.
• Tolerance: Immunological tolerance is the goal of therapy and can last for years after treatment is discontinued.

| Parameter | Value |

|---|---|

| Bioavailability | Low (Subcutaneous); Variable (Oral) |

| Protein Binding | Variable; high for specific alkaloids |

| Half-life | 2-6 hours (systemic components) |

| Tmax | 30-60 minutes (subcutaneous) |

| Metabolism | Proteolysis; Hepatic (COMT/MAO) |

| Excretion | Renal (Metabolites); Fecal (Trace) |

• Source: Flowering tops of Ornithogalum umbellatum.
• Key Components: Convallatoxin, Convalloside, Flavonoids, and specific allergenic proteins.
• Solubility: Soluble in aqueous solutions and saline buffers used for clinical extraction.

It is classified as a Standardized Chemical Allergen and an Adrenergic Agonist. It belongs to the broader category of Biological Response Modifiers and Sympathomimetic Agents.